论文部分内容阅读
目的探讨三维适形放射治疗(3DCRT)联合顺铂(DDP)和5氟尿嘧啶(5-Fu)的(DF)方案化疗治疗食管癌的临床疗效。方法将收治的67例食管癌患者随机分为治疗组(32例)和对照组(35例),对照组患者给予3DCRT放射治疗,治疗组患者在3DCRT放射治疗基础上加用DF方案化疗。比较两组患者近期疗效,1年、2年和3年生存率,治疗完成后患者卡氏评分情况及不良反应情况。结果治疗组和对照组患者1年生存率(82.9%和59.4%)、2年生存率(45.7%和34.4%)和3年生存率(37.1%和25.0%)比较,差异均有统计学上意义(P<0.05)。治疗组患者KPS评分提高、稳定、降低分别为45.7%、51.4%和2.9%,对照组患者分别为31.3%、56.3%和12.5%,两组患者提高和降低间差异有统计学意义(P<0.05)。治疗组患者不良反应发生率为60.0%,对照组为43.8%,两组比较,差异无统计学意义(2=1.15 P>0.05)。结论 3DCRT联合DF方案化疗治疗食管癌疗效确切,提高了患者1年、2年、3年生存率及生活质量,且不良反应发生率不增加。
Objective To investigate the clinical efficacy of three-dimensional conformal radiotherapy (3DCRT) combined with cisplatin (DDP) and 5-fluorouracil (DF) regimen in the treatment of esophageal cancer. Methods Sixty-seven patients with esophageal cancer were randomly divided into treatment group (n = 32) and control group (n = 35). Patients in control group were treated with 3DCRT radiotherapy. Patients in treatment group were treated with DF regimen based on 3DCRT radiotherapy. The short-term efficacy, 1-year, 2-year and 3-year survival rates were compared between the two groups. The patient’s Karnofsky scores and adverse reactions after treatment were compared. Results The 1-year survival rates (82.9% vs 59.4%), 2-year survival rates (45.7% vs 34.4%) and 3-year survival rates (37.1% vs 25.0%) in the treatment group and the control group were statistically different Significance (P <0.05). The KPS scores in the treatment group were increased, stabilized and decreased by 45.7%, 51.4% and 2.9%, respectively, while those in the control group were 31.3%, 56.3% and 12.5%, respectively. There was a significant difference between the two groups in increasing and decreasing KPS scores (P < 0.05). The incidence of adverse reactions was 60.0% in the treatment group and 43.8% in the control group. There was no significant difference between the two groups (2 = 1.15 P> 0.05). Conclusions 3DCRT combined with DF regimen chemotherapy is effective in treating esophageal cancer, which improves the patients’ 1-year, 2-year, 3-year survival rate and quality of life, and the incidence of adverse reactions does not increase.